BioNTech Appoints Ramón Zapata as New Chief Financial Officer
BioNTech SE (Nasdaq: BNTX), a frontrunner in the biopharmaceutical industry, has made a significant leadership change by appointing Ramón Zapata-Gomez as the new Chief Financial Officer (CFO). This transition is set to take effect on July 1, 2025, as he replaces Jens Holstein, who intends to retire at the end of June.
Leadership Transition and Future Directions
Ramón Zapata joins BioNTech from Novartis AG, where he served as CFO in their global biomedical research organization since 2022. His extensive background in the pharmaceutical sector equips him well for this crucial role. At BioNTech, Zapata will focus on steering the company’s financial strategies to align with its ambition to evolve into a multi-product entity within the oncology market.
Key Responsibilities as CFO
In his upcoming position, Zapata will enhance BioNTech's financial architecture, ensuring that it supports the launches of new oncology products. His strategic vision includes optimizing financial performance in key markets, driving excellence in financial reporting, accounting, treasury, and supply chain management.
Insights from BioNTech Leadership
Helmut Jeggle, the Chairman of the Supervisory Board at BioNTech, praised Zapata’s proven expertise. “Ramón Zapata is an accomplished leader with deep finance expertise who will be taking over from Jens Holstein at an exciting phase,” Jeggle remarked. He also acknowledged Holstein’s instrumental role in augmenting BioNTech's financial stability and operational efficiency throughout his tenure.
Jens Holstein’s Contributions
Reflecting on his time at BioNTech, Jens Holstein expressed gratitude for the opportunity to contribute to the company's remarkable growth. He stated, “It has been a privilege to be part of the development of BioNTech into one of the largest global biotechnology companies.” Holstein plans to focus on non-executive roles following his retirement.
Ramón Zapata's Vision and Experience
Ramón Zapata, bringing over 25 years of experience, has a robust background in the pharmaceutical and consumer goods industries. He has held pivotal roles in esteemed companies such as Novartis AG and Mondel?z International. His expertise includes the seamless execution of finance functions from drug discovery to market, emphasizing M&A transactions and leading digital finance transformations.
Academic and Professional Credentials
Zapata holds dual citizenship of the United States and Mexico. He is a Certified Public Accountant from Universidad Panamericana in Mexico City and earned an MBA from IPADE Business School in Mexico City and IESE Business School in Barcelona, Spain.
About BioNTech SE
BioNTech, at the forefront of innovative cancer therapies, is dedicated to advancing next-generation immunotherapy solutions. The company's expansive oncology portfolio includes mRNA cancer immunotherapies and next-generation immunomodulators, aiming to tackle various cancer stages effectively. Alongside its robust pipeline, BioNTech collaborates with numerous pharmaceutical partners to develop transformative biopharmaceuticals and vaccines for infectious diseases.
Frequently Asked Questions
Who is the new CFO of BioNTech?
Ramón Zapata has been appointed as the new Chief Financial Officer of BioNTech, effective July 1, 2025.
What was the reason for the leadership change at BioNTech?
Jens Holstein, the former CFO, is retiring at the end of June 2025, and Ramón Zapata will succeed him to support BioNTech's strategic growth.
What experience does Ramón Zapata have?
Ramón Zapata has over 25 years of experience in finance and leadership roles within the pharmaceutical and consumer goods sectors, including CFO at Novartis AG.
What are BioNTech's plans in oncology?
BioNTech aims to launch multiple oncology products and transform into a multi-product company focusing on innovative cancer treatments.
How does BioNTech support its product development?
BioNTech leverages extensive collaborations with various pharmaceutical companies and utilizes cutting-edge technology to advance its research and product commercialization.
